Altre lingue Nurix Therapeutics, Inc.

Azioni

NRIX

US67080M1036

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
12,36 ^USD	0,00%		-8,98%	+19,77%

12/04	Aggiornamento settoriale: titoli del settore sanitario stabili prima della campanella di venerdì	MT
12/04	Aggiornamento settoriale: Assistenza sanitaria	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	17/04
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	15/04
Sector Update: Health Care Stocks Steady Pre-Bell Friday	12/04
Sector Update: Health Care	12/04
North American Morning Briefing : Big Banks Kick off Earnings Season	12/04
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	12/04
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	12/04
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours	11/04
Nurix Therapeutics Announces Proposed Public Offering	11/04
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update	10/04
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M	10/04
North American Morning Briefing : Traders Await -2-	10/04
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	09/04
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	09/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	09/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	09/04
Nurix Therapeutics to Participate in Upcoming Investor Conferences	03/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nurix Therapeutics, Inc.

Azioni

NRIX

US67080M1036

Altre lingue

Filtri